Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep 4:21:192-204.
doi: 10.1016/j.omtn.2020.05.025. Epub 2020 May 23.

Aptamers Against Live Targets: Is In Vivo SELEX Finally Coming to the Edge?

Mayte Sola  1 , Ashwathi Puravankara Menon  1 , Beatriz Moreno  1 , Daniel Meraviglia-Crivelli  1 , Mario Martínez Soldevilla  1 , Fernando Cartón-García  1 , Fernando Pastor  2
Affiliations
Review

Aptamers Against Live Targets: Is In Vivo SELEX Finally Coming to the Edge?

Mayte Sola et al. Mol Ther Nucleic Acids. .

Abstract

Targeted therapeutics underwent a revolution with the entry of monoclonal antibodies in the medical toolkit. Oligonucleotide aptamers form another family of target agents that have been lagging behind in reaching the clinical arena in spite of their potential clinical translation. Some of the reasons for this might be related to the challenge in identifying aptamers with optimal in vivo specificity, and the nature of their pharmacokinetics. Aptamers usually show exquisite specificity, but they are also molecules that display dynamic structures subject to changing environments. Temperature, ion atmosphere, pH, and other variables are factors that could determine the affinity and specificity of aptamers. Thus, it is important to tune the aptamer selection process to the conditions in which you want your final aptamer to function; ideally, for in vivo applications, aptamers should be selected in an in vivo-like system or, ultimately, in a whole in vivo organism. In this review we recapitulate the implementations in systematic evolution of ligands by exponential enrichment (SELEX) to obtain aptamers with the best in vivo activity.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1
Figure 1
Depiction of the Steps of Conventional Systematic Evolution of Ligands by Exponential Enrichment (SELEX)
Figure 2
Figure 2
Sequential Steps in Cell-SELEX
Figure 3
Figure 3
Whole-Organism In Vivo SELEX
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Zhou J., Rossi J.J. Cell-type-specific, aptamer-functionalized agents for targeted disease therapy. Mol. Ther. Nucleic Acids. 2014;3:e169. - PMC - PubMed
    1. Zhou J., Rossi J. Aptamers as targeted therapeutics: current potential and challenges. Nat. Rev. Drug Discov. 2017;16:181–202. - PMC - PubMed
    1. Geiger A., Burgstaller P., von der Eltz H., Roeder A., Famulok M. RNA aptamers that bind l-arginine with sub-micromolar dissociation constants and high enantioselectivity. Nucleic Acids Res. 1996;24:1029–1036. - PMC - PubMed
    1. Chen L., Rashid F., Shah A., Awan H.M., Wu M., Liu A., Wang J., Zhu T., Luo Z., Shan G. The isolation of an RNA aptamer targeting to p53 protein with single amino acid mutation. Proc. Natl. Acad. Sci. USA. 2015;112:10002–10007. - PMC - PubMed
    1. Musumeci D., Platella C., Riccardi C., Moccia F., Montesarchio D. Fluorescence sensing using DNA aptamers in cancer research and clinical diagnostics. Cancers (Basel) 2017;9:E174. - PMC - PubMed

LinkOut - more resources